Liquidia Technologies (LQDA) Moves 5.7% Higher: Will This Strength Last?

Stock Performance - Liquidia Technologies Inc (LQDA) shares rallied 5 7% in the last trading session closing at $13 62 driven by higher trading volume compared to a typical session [1] - The stock has gained 12 7% over the past four weeks [1] Product Development - The stock price rise is likely due to anticipation of final FDA approval and launch of Yutrepia (treprostinil) inhalation powder in 2025 which received temporary FDA approval in 2023 [2] - Yutrepia is indicated for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease [2] Financial Expectations - The company is expected to post a quarterly loss of $0 39 per share representing a year-over-year improvement of +7 1% [3] - Revenues are expected to be $5 13 million up 13 2% from the year-ago quarter [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days [4] Industry Comparison - Liquidia Technologies is part of the Zacks Medical - Biomedical and Genetics industry [4] - Puma Biotech (PBYI) another stock in the same industry closed the last trading session 0 3% higher at $2 98 and has returned 5 7% in the past month [4] - For Puma Biotech the consensus EPS estimate for the upcoming report has changed +50% over the past month to $0 14 representing a change of -54 8% from the year-ago quarter [5] Stock Ratings - Liquidia Technologies currently carries a Zacks Rank 2 (Buy) [4] - Puma Biotech currently has a Zacks Rank of 3 (Hold) [5]